logo

HER-2 Negative Breast Cancer Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The HER-2 Negative Breast Cancer Market is segmented By Type of Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, and Others), and Geography.

Home Industry Reports Healthcare HER-2 Negative Breast Cancer Market - Growth, Trends, COVID-19 Impact, and Forec ...

HER-2 Negative Breast Cancer Market Snapshot

HER-2 Negative Breast Cancer Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >8.2 %
HER-2 Negative Breast Cancer Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The human epidermal growth factor receptor 2 (HER-2) negative breast cancer refers to the cancerous cells in the breast which do not contain high levels of protein HER-2. The major requirement in the present decade is to improve upon the maximising the symptom control and extending survival. In all types of breast cancers, one of the major drawback is that despite the advancements in the treatment of early stage of breast cancers, the recurrence of the disease among the patients is quite common. While, HER-2 positive is highly prevalent across all geographies, the presence of HER-2 negative is also steadily growing and clinical advancement as well as research development activities in this direction is expected to grow better over the forecast period. The high cost of treatment and availability of alternative treatments are expected to restrict the growth of this market.

Scope of the Report

The HER-2 negative breast cancer is of less occurrence among the women and accounts for about 15% of all types of breast cancers. The studied market is segmented by type of treatment and geography.

By Type of Treatment
Chemotherapy
Radiation
Hormonal Therapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Treatment via Hormonal therapy is Expected to be the Major Contributor to the Market

  • There are several drugs approved in the market which can block the hormones or lower their levels in the body, which helps in treatment of HER-2 negative breast cancer. Some of the well-established drugs include tamoxifen, fulvestrant, goserelin, olaparib, and others.
  • Some of the companies advancing their drugs development and R&D activities in this sub-segment of the market include AstraZeneca, Biomarin, Abbvie, Merck and Co. Inc., and Tesaro, with their products in the late the stage of clinical development.
  • One of the challenges among the manufacturers is the occurrence of resistance is common problem in hormonal therapy. Therefore, combination therapy with hormonal therapy to prevent or overcome the hormone resistance is highly considered and are into development.
HER-2 Negative Breast Cancer Market Share

North America is Expected to Hold a Significant Share in the Market with Similar Trend in the Forecast Period

North America expected to hold a major market share in the global HER-2 negative breast cancer market owing to better healthcare infrastructure, and growing number of foundations and independent venture groups supporting the biopharmaceutical manufacturers. The presence of major manufacturers across the different states, getting funding from different venture partners drives the market related to HER-2 negative breast cancer. As per the American cancer Society, 2017-2018, the negative HER-2 cancers are twice as common in the black women as compared to white women in the United States, also more common in the in pre-menopausal women and those with a BRCA1 gene mutation. The challenges associated within such population is early diagnosis and right treatment procedure to the identified set of patient population with the HER-2 negative breast cancers. The availability of good government support along with better disposable income option among all populations as well as good percentage of medical tourism across the North America region, fuels the market growth.

HER-2 Negative Breast Cancer Market Growth

Competitive Landscape

The major focus among the companies is to develop combination therapies which shall overcome the resistance of existing drug therapies in the market thus boosting the targeted disease treatment. This is done via collaboration, and partnerships among the market players. Some of the major companies in this segment include AstraZeneca, Eli Lilly and Company, Novartis AG, Pfizer, GSK, and others.

AstraZeneca, Eli Lilly and Company, Novartis AG, Pfizer, GSK

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Breast Cancers

      2. 4.2.2 Medical Advancements by Breast Cancers Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 Less Awareness Regarding HER-2 Negative Breast Cancer

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Treatment

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Radiation

      3. 5.1.3 Hormonal Therapy

      4. 5.1.4 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Celgene Corporation (Bristol Myers Squibb Company)

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 GlasxoSmithKline

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Novartis AG

      7. 6.1.7 Pfizer

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The HER-2 Negative Breast Cancer Market market is studied from 2018 - 2026.

The HER-2 Negative Breast Cancer Market is growing at a CAGR of >8.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lilly and Company , AstraZeneca, GSK, Novartis AG , Pfizer are the major companies operating in HER-2 Negative Breast Cancer Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!